期刊文献+

Skeletal myoblast based delivery of angiogenic growth factors:a comparison between angiopoietin-1 and VEGF gene delivery for therapeutic angiogenesis in the heart 被引量:3

Skeletal myoblast based delivery of angiogenic growth factors:a comparison between angiopoietin-1 and VEGF gene delivery for therapeutic angiogenesis in the heart
下载PDF
导出
摘要 Objectives This study investigated the efficacy of human skeletal myoblasts (SkM) mediated either human vascular endothelial growth factor-165 (hVEGF165) or angiopoietin-1 (Ang-1) on vascular development and myocardial regional perfusion. Methods A porcine heart model of chronic infarction was created in 28 female swine by coronary artery ligation. The animals were randomized into: (1) group-1, DMEM injected (n=6), (2) group-2, Ad-null transduced SkM transplanted (n=6), (3) group-3, Ad-hVEGF165 transduced SkM transplanted (n=8), and (4) group-4, Ad-Ang-1 transduced SkM (n=8). Three weeks later, 5 ml DMEM containing 3×108 SkM carrying exogenous genes were intramyocardially injected into 20 sites in left ventricle in groups-2, -3 and -4. Animals in group-1 were injected 5 ml DMEM without cells. Animals were kept on 5 mg/kg cyclosporine per day for 6 weeks. Regional blood flow was measured using fluorescent microspheres. The heart was explanted at 2, 6 and 12 weeks after transplantation for histological studies. Results Histological examination showed survival of lac-z expressing myoblasts in host tissue. Capillary density based on Von Willebrand factor-VIII (vWF-VIII) at low power field (×100) was 57.13±11.85 in group-3 at 6 weeks and declined to 32.1±5.21 at 12 weeks, while it was 39.9±10.26 at 6 weeks and increased to 45.14±6.54 at 12 weeks in group-4. The mature blood vessel index was highest in group- 4 at 6 and 12 weeks after transplantation. The regional blood flow in the center and peri-infarct area was significantly increased in animals of groups-3 and -4. Conclusions SkM carrying either hVEGF165 or Ang-1 induced neovascularization with increased blood flow. Ang-1 overexpression resulted in mature and stable blood vessel formation and may be a more potent arteriogenic inducer for neovascularization. Objectives This study investigated the efficacy of human skeletal myoblasts (SkM) mediated either human vascular endothelial growth factor-165 (hVEGF165) or angiopoietin-1 (Ang-1) on vascular development and myocardial regional perfusion. Methods A porcine heart model of chronic infarction was created in 28 female swine by coronary artery ligation. The animals were randomized into: (1) group-1, DMEM injected (n=6), (2) group-2, Ad-null transduced SkM transplanted (n=6), (3) group-3, Ad-hVEGF165 transduced SkM transplanted (n=8), and (4) group-4, Ad-Ang-1 transduced SkM (n=8). Three weeks later, 5 ml DMEM containing 3×108 SkM carrying exogenous genes were intramyocardially injected into 20 sites in left ventricle in groups-2, -3 and -4. Animals in group-1 were injected 5 ml DMEM without cells. Animals were kept on 5 mg/kg cyclosporine per day for 6 weeks. Regional blood flow was measured using fluorescent microspheres. The heart was explanted at 2, 6 and 12 weeks after transplantation for histological studies. Results Histological examination showed survival of lac-z expressing myoblasts in host tissue. Capillary density based on Von Willebrand factor-VIII (vWF-VIII) at low power field (×100) was 57.13±11.85 in group-3 at 6 weeks and declined to 32.1±5.21 at 12 weeks, while it was 39.9±10.26 at 6 weeks and increased to 45.14±6.54 at 12 weeks in group-4. The mature blood vessel index was highest in group- 4 at 6 and 12 weeks after transplantation. The regional blood flow in the center and peri-infarct area was significantly increased in animals of groups-3 and -4. Conclusions SkM carrying either hVEGF165 or Ang-1 induced neovascularization with increased blood flow. Ang-1 overexpression resulted in mature and stable blood vessel formation and may be a more potent arteriogenic inducer for neovascularization.
出处 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2006年第3期152-160,共9页 老年心脏病学杂志(英文版)
关键词 therapeutic angiogenesis SKELETAL MYOBLASTS vascular ENDOTHELIAL growth factor-165 ANGIOPOIETIN-1 MYOCARDIAL INFARCTION therapeutic angiogenesis skeletal myoblasts vascular endothelial growth factor-165 angiopoietin-1 myocardial infarction
  • 相关文献

参考文献29

  • 1[1]Ye L,Haider HKh,Sim EKW.Adult stem cells for cardiac repair:a choice between skeletal myoblasts and bone marrow stem cells.Exp Biol Med 2006;231:8-19.
  • 2[2]Haider HKh,Ashraf M.Bone marrow stem cell transplantation for cardiac repair.Am J Physiol Heart Circ Physiol 2005;288:H2557-67.
  • 3[3]Murry CE,Field L J,Menasche P.Cell-based cardiac repair:reflections at the 10-year point.Circulation 2005;112:3174-83.
  • 4[4]Haider HKh,Tan AC,Aziz S,et al.Myoblast transplantation for cardiac repair:a clinical perspective.Mol Ther 2004;9:14-23.
  • 5[5]Sim EKW,Jiang S J,Ye L,et al.Human skeletal myoblast transplant in heart failure.J Card Surg 2003;18:319-27.
  • 6[6]Ye L,Haider HKh,Jiang S J,Sim EKW.Therapeutic angiogenesis.Devising new strategies based on past experiences.Basic Res Cardiol 2004;99:121-32.
  • 7[7]Ye L,Haider HKh,Jiang S J,et al.High efficiency transduction of humanVEGF165 into human skeletal myoblast:in vitro studies.Exp Mol Med 2003;35:412-20.
  • 8[8]Ye L,Haider HKh,Jiang S J,et al.Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model.Eur J Heart Fail 2005;7:945-52.
  • 9[9]Rosengart TK,Lee LY,Patel SR,et al.Angiogenesis gene therapy:phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.Circulation 1999;100:468-74,
  • 10[10]Symes JF,Losordo DW,Vale PR,et al.Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.Ann Thorac Surg 1999;68:830-6.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部